# US 2012/0252844 A1 · 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252844 A1
- Document ID: US20120252844A1
- Status: Published application
- Kind: A1
- Application number: 13/432,382
- Filed: 2012-03-28
- Published: 2012-10-04
- Earliest claimed: 2011-03-28
- Assignees: Deuteria Pharmaceuticals, Inc.
- Inventors: Sheila DeWitt
- Web page: https://patentgrep.com/patent/US20120252844A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07B 59/002: {Heterocyclic compounds}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present application describes 2-(2′,6′-dioxo-3′-deutero-piperidin-3′-yl)isoindoles, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

## Claims

### Claim 1

A deuterium-enriched compound of formula I or a stereoisomer or pharmaceutically acceptable salt thereof:
wherein:
one of R8-R8a is —(CR9R10)nA and the other is selected from H and D;
alternatively, R8a is —OR12a, and R8 is selected from H and D;
A is N11R12;
alternatively, when n=1, then A is selected from D, H, and NR11R12;
one of X and Y is C═O and the other is selected from CH2, CHD, CD2, and C═O;
Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
R1-R7 and R9-R10 are independently selected from H and D;
R11 is selected from H, D, and CH3;
R12 is selected from H, D, (C1-C8)alkyl, (C3-C7)cycloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, (C0-C4)alkyl-(C2-C9)heteroaryl, C(O)R13, C(S)R13, C(O)OR14, (C1-C8)alkyl-N(R16)2, (C1-C8)alkyl-OR15, (C1-C8)alkyl-C(O)OR15, C(O)NHR13, C(S)NHR13, C(O)NR13R13′, C(S)NR13R13′, and (C1-C8)alkyl-O(CO)R15;
provided that when n=0, R12 is other than H or D;
R12a is selected from CH2—Ra—Rb—Rc, H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-(C3-C7)cycloalkyl, C(O)(C1-C8)alkyl, C(O)O(C1-C8)alkyl, C(O)NH(C1-C8)alkyl, C(O)N((C1-C8)alkyl)2, C(O)(C3-C7)cycloalkyl, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, (C0-C4)alkyl-(C2-C9)heteroaryl, C(O)aryl, C(O)(C1-C6)heterocycloalkyl, and C(O)(C2-C9)heteroaryl, and R12a is optionally substituted with 1-3 groups selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, ═O, NR202, CO2R20, C(O)NH(C1-C8)alkyl, C(O)N((C1-C8)alkyl)2, NO2, —CN, OH, halogen, and S(O)2(C1-C8)alkyl;
Ra is a bond, alternatively, Ra is selected from aryl, (C1-C6)heterocycloalkyl, and (C2-C9)heteroaryl, wherein Ra is optionally substituted with 1-3 halogen;
Rb is selected from (CH2)m, O(CH2)m, and (CH2)mO;
m is selected from 0-3;
Rc is selected from aryl, (C1-C6)heterocycloalkyl, and (C2-C9)heteroaryl, and Rc is substituted 0-2 groups selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, ═O, NR202, CO2R20, —CN, OH, halogen, S(O)2(C1-C8)alkyl, aryl substituted with 0-2 Rd, and (C2-C9)heteroaryl substituted with 0-2 Rd;
Rd is selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, CONR202, CO2(C1-C6)alkyl, and CO2(C1-C6)haloalkyl;
R13 is selected from H, (C1-C8)alkyl, (C3-C7)cycloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, (C0-C4)alkyl-(C2-C9)heteroaryl, (C0-C8)alkyl-N(R16)2, (C1-C8)alkyl-OR15, (C1-C8)alkyl-C(O)OR15, (C1-C8)alkyl-O(CO)R15, and C(O)OR15;
R13′ is selected from (C1-C8)alkyl, (C3-C7)cycloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, (C0-C4)alkyl-(C2-C9)heteroaryl, (C0-C8)alkyl-N(R16)2, (C1-C8)alkyl-OR15, (C1-C8)alkyl-C(O)OR15, (C1-C8)alkyl-O(CO)R15, and C(O)OR15;
R14 is selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C1-C4)alkyl-OR15, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, and (C0-C4)alkyl-(C2-C9)heteroaryl;
R15 is selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-aryl, and (C2-C9)heteroaryl;
R16, at each occurrence, is independently selected from H, D, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-aryl, (C2-C9)heteroaryl, and (C0-C8)alkyl-C(O)OR15;
alternatively, N(R16)2 forms a heterocycloalkyl group;
n, at each occurrence, is selected from 0, 1, 2, and 3;
the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted with 1-3 R17;
R17, at each occurrence, is independently selected from H, D, halogen, NO2, —CN, (C1-C8)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, (C1-C6)alkyenedioxy, —NHC(O)(C1-C6)alkyl, CH2OCH3, CH2CH2OCH3, S—(C1-C8)alkyl, SO2(C1-C8)alkyl, S—(C1-C8)haloalkyl, SO2(C1-C8)haloalkyl, (C0-C4)alkyl-R17a, (C0-C4)alkyl-R18, —O—(C0-C4)alkyl-R18, —(CH2—R19)p—R18, OC(O)(CH2)pNH2, and OC(O)(CH2)p(C1-C6)heterocycloalkyl;
p, at each occurrence, is selected from 0, 1, and 2;
R17a, at each occurrence, is independently selected from OH, NH2, and CO2R20;
R18, at each occurrence, is independently selected from aryl, (C1-C6)heterocycloalkyl, and (C2-C9)heteroaryl, wherein each aryl, heterocycloakyl, and heteroaryl is optionally substituted with 1-3 (C1-C8)alkyl;
R19, at each occurrence, is independently selected from CH2, NH, and O;
R20 is selected from H and (C1-C8)alkyl;
wherein a hydrogen atom present in any of the substituents is optionally replaced by deuterium.

### Claim 2 (depends on 1)

A deuterium-enriched compound of claim 1, wherein:
wherein:
R8 is —(CR9R10)NR11R12;
R8a is selected from H and D;
X is CH2;
Y is C═O;
Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
R1-R7 and R9-R10 are independently selected from H and D;
R11 is selected from H and D;
R12 is selected from C(O)R13 and C(O)OR14;
R13 is selected from (C1-C8)alkyl, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C2-C9)heteroaryl, and (C1-C6)alkyl-C(O)OR15;
R14 is (C1-C8)alkyl;
R15 is selected from H and (C1-C8)alkyl;
the aryl and heteroaryl groups are optionally substituted with 1-3 R17;
R17, at each occurrence, is independently selected from H, D, halogen, (C1-C8)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, S—(C1-C8)alkyl, and SO2(C1-C8)alkyl;
wherein a hydrogen atom is present in any of the substituents it is optionally replaced by deuterium.

### Claim 3 (depends on 1)

A deuterium-enriched compound of claim 1, wherein:
R8 is selected from H and D;
R8a is —OR12a
X is CH2;
Y is C═O;
Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
R1-R7 and R9-R10 are independently selected from H and D;
R12a is selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-(C3-C7)cycloalkyl, C(O)(C1-C8)alkyl, C(O)O(C1-C8)alkyl, C(O)NH(C1-C8)alkyl, C(O)N((C1-C8)alkyl)2, C(O)(C3-C7)cycloalkyl, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, (C0-C4)alkyl-(C2-C9)heteroaryl, C(O)aryl, C(O)(C1-C6)heterocycloalkyl, and C(O)(C2-C9)heteroaryl, and R12a is optionally substituted with 1-3 groups selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, NR202, CO2R20, C(O)NH(C1-C8)alkyl, C(O)N((C1-C8)alkyl)2, NO2, —CN, OH, halogen, and S(O)2(C1-C8)alkyl;
R20 is selected from H and (C1-C8)alkyl;
wherein a hydrogen atom is present in any of the substituents it is optionally replaced by deuterium.

### Claim 4 (depends on 1)

A deuterium-enriched compound of claim 1, wherein:
R8 is selected from H and D;
R8a is —OR12a
one of X and Y is C═O and the other is selected from CH2, CHD, CD2, and C═O;
Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
R1-R7 and R9-R10 are independently selected from H and D;
R12a is CH2—Ra—Rb—Rc;
Ra is a bond, alternatively, Ra is selected from aryl, (C1-C6)heterocycloalkyl, and (C2-C9)heteroaryl, wherein Ra is optionally substituted with 1-3 halogen;
Rb is selected from (CH2)m, O(CH2)m, and (CH2)mO;
m is selected from 0-3;
Rc is selected from aryl, (C1-C6)heterocycloalkyl, and (C2-C9)heteroaryl, and Rc is substituted 0-2 groups selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, ═O, NR202, CO2R20, —CN, OH, halogen, S(O)2(C1-C8)alkyl, aryl substituted with 0-2 Rd, and (C2-C9)heteroaryl substituted with 0-2 Rd;
Rd is selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, CONR202, CO2(C1-C6)alkyl, and CO2(C1-C6)haloalkyl;
wherein a hydrogen atom present in any of the substituents is optionally replaced by deuterium.

### Claim 5 (depends on 1)

A deuterium-enriched compound of claim 1, wherein:
R8 is —(CR9R10)nNR11R12;
R8a is selected from H and D;
one of X and Y is C═O and the other is selected from CH2, CHD, CD2, and C═O;
Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
R1-R7 and R9-R10 are independently selected from H and D;
R11 is selected from H and D;
R12 is selected from C(O)NHR13 and C(O)NR13R13′;
R13 is selected from aryl;
R13′ is (C1-C8)alkyl;
n, at each occurrence, is selected from 0, 1, 2, and 3;
the aryl group is substituted with 2 R17;
R17, at each occurrence, is independently selected from H, halogen, NO2, (C1-C8)alkyl, —NHC(O)(C1-C6)alkyl, (C0-C4)alkyl-R17a, (C0-C4)alkyl-R18, —O—R18, —(CH2—R19)p—R18, OC(O)(CH2)pNH2, and OC(O)(CH2)p(C1-C6)heterocycloalkyl;
p, at each occurrence, is selected from 0, 1, and 2;
R17a, at each occurrence, is independently selected from OH and NH2;
R18, at each occurrence, is independently selected from aryl, (C1-C6)heterocycloalkyl, and (C2-C9)heteroaryl, wherein each aryl, heterocycloakyl, and heteroaryl is optionally substituted with 1-3 (C1-C8)alkyl;
R19, at each occurrence, is independently selected from CH2, NH, and O;
wherein a hydrogen atom present in any of the substituents is optionally replaced by deuterium.

### Claim 6 (depends on 1)

A deuterium-enriched compound of claim 1, wherein:
R8 is selected from H and D;
R8a is —(CR9R10)A is NR11R12;
X is CH2;
Y is C═O;
Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
R1-R7 and R9-R10 are independently selected from H and D;
R11 is CH3;
R12 is selected from H, D, (C1-C8)alkyl, (C3-C7)cycloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, (C0-C4)alkyl-(C2-C9)heteroaryl, C(O)R13, C(S)R13, C(O)OR14, (C1-C8)alkyl-N(R16)2, (C1-C8)alkyl-OR15, (C1-C8)alkyl-C(O)OR15, C(O)NHR13, C(S)NHR13, C(O)NR13R13′, C(S)NR13R13′, and (C1-C8)alkyl-O(CO)R15;
R13 is selected from H, (C1-C8)alkyl, (C3-C7)cycloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, (C0-C4)alkyl-(C2-C9)heteroaryl, (C0-C8)alkyl-N(R16)2, (C1-C8)alkyl-OR15, (C1-C8)alkyl-C(O)OR15, (C1-C8)alkyl-O(CO)R15, and C(O)OR15;
R13′ is selected from (C1-C8)alkyl, (C3-C7)cycloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, (C0-C4)alkyl-(C2-C9)heteroaryl, (C0-C8)alkyl-N(R16)2, (C1-C8)alkyl-OR15, (C1-C8)alkyl-C(O)OR15, (C1-C8)alkyl-O(CO)R15, and C(O)OR15;
R14 is selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C1-C4)alkyl-OR15, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, and (C0-C4)alkyl-(C2-C9)heteroaryl;
R15 is selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-aryl, and (C2-C9)heteroaryl;
R16, at each occurrence, is independently selected from H, D, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-aryl, (C2-C9)heteroaryl, and (C0-C8)alkyl-C(O)OR15;
alternatively, N(R16)2 forms a heterocycloalkyl group;
n, at each occurrence, is selected from 0, 1, 2, and 3;
the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted with 1-3 R17;
R17, at each occurrence, is independently selected from H, D, halogen, NO2, (C1-C8)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, (C1-C6)alkyenedioxy; —NHC(O)(C1-C6)alkyl, CH2OCH3, CH2CH2OCH3, S—(C1-C8)alkyl, SO2(C1-C8)alkyl, (C0-C4)alkyl-R17a, (C0-C4)alkyl-R18, —O—(C0-C4)alkyl-R18, —(CH2—R19)p—R18, OC(O)(CH2)pNH2, and OC(O)(CH2)p(C1-C6)heterocycloalkyl;
p, at each occurrence, is selected from 0, 1, and 2;
R17a, at each occurrence, is independently selected from OH, NH2, and CO2R20;
R18, at each occurrence, is independently selected from aryl, (C1-C6)heterocycloalkyl, and (C2-C9)heteroaryl, wherein each aryl, heterocycloakyl, and heteroaryl is optionally substituted with 1-3 (C1-C8)alkyl;
R19, at each occurrence, is independently selected from CH2, NH, and O;
R20 is selected from H and (C1-C8)alkyl;
wherein a hydrogen atom present in any of the substituents is optionally replaced by deuterium.

### Claim 7 (depends on 6)

A deuterium-enriched compound of claim 6, wherein:
R12 is selected from C(O)R13, C(O)OR14, C(O)NHR13, and C(O)NR13R13′;
R13 is selected from H, (C1-C8)alkyl, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C2-C9)heteroaryl, and (C0-C8)alkyl-N(R16)2;
R13′ is selected from (C1-C8)alkyl, (C0-C4)alkyl-aryl, and (C0-C4)alkyl-(C2-C9)heteroaryl;
R14 is selected from (C1-C8)alkyl;
R15 is (C1-C8)alkyl;
R16, at each occurrence, is independently selected from H, D, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C0-C4)alkyl-aryl, (C2-C9)heteroaryl, and (C0-C8)alkyl-C(O)OR15;
the aryl and heteroaryl groups are optionally substituted with 1-3 R17;
R17, at each occurrence, is independently selected from halogen, (C1-C8)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, and (C1-C6)alkyenedioxy;
wherein a hydrogen atom present in any of the substituents is optionally replaced by deuterium.

### Claim 8 (depends on 1)

A deuterium-enriched compound of claim 1, wherein:
R8 is —(CR9R10)nNR11R12;
R8a is selected from H and D;
X is CH2;
Y is C═O;
Z is H or D, provided that the abundance of deuterium in Z is at least 30%;
R1-R7 and R9-R10 are independently selected from H and D;
R11 is selected from H and D;
R12 is selected from (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C2-C9)heteroaryl, C(O)R13, C(S)R13, C(O)OR14, C(O)NHR13, and C(S)NHR13;
R13 is selected from (C1-C8)alkyl, (C0-C4)alkyl-aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, (C0-C4)alkyl-(C2-C9)heteroaryl, and (C1-C8)alkyl-C(O)OR15;
R14 is selected from (C1-C8)alkyl;
R15 is selected from H and (C1-C8)alkyl;
n, at each occurrence, is selected from 0 and 1;
the heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted with 1-3 R17;
R17, at each occurrence, is independently selected from halogen, —CN, (C1-C8)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, (C1-C6)alkyenedioxy, S—(C1-C8)alkyl, SO2(C1-C8)alkyl, S—(C1-C8)haloalkyl, and SO2(C1-C8)haloalkyl;
wherein a hydrogen atom present in any of the substituents is optionally replaced by deuterium.

### Claim 9 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the compound is of formula Ia or a pharmaceutically acceptable salt thereof:

### Claim 10 (depends on 9)

A deuterium-enriched compound of claim 9, wherein:
X and Y are C═O;
n is 1;
R12 is C(O)R13; and
R13 is selected from (C1-C8)alkyl and (C3-C7)cycloalkyl.

### Claim 11 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the compound is of formula Ib or a pharmaceutically acceptable salt thereof:

### Claim 12 (depends on 11)

A deuterium-enriched compound of claim 11, wherein:
X and Y are C═O;
n is 1;
R12 is C(O)R13; and
R13 is selected from (C1-C8)alkyl and (C3-C7)cycloalkyl.

### Claim 13 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the compound is of formula II, or a stereoisomer or pharmaceutically acceptable salt thereof:
wherein:
R12a-R12e are independently selected from H and D.

### Claim 14 (depends on 13)

A deuterium-enriched compound of claim 13, wherein the compound is of formula IIa, or pharmaceutically acceptable salt thereof:
wherein:
R12a-R12e are independently selected from H and D.

### Claim 15 (depends on 13)

A deuterium-enriched compound of claim 13, wherein the compound is of formula IIb, or a stereoisomer or pharmaceutically acceptable salt thereof:
wherein:
R12a-R12e are independently selected from H and D.

### Claim 16 (depends on 1)

A deuterium-enriched compound claim 1, or stereoisomer or pharmaceutically acceptable salt thereof, wherein: the abundance of deuterium in Z is selected from: (a) at least 40%, (b) at least 50%, (c) at least 60%, (d) at least 70%, (e) at least 80%, (f) at least 90%, (g) at least 95%, (h) at least 97%, and (i) about 100%.

### Claim 17 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the compound is of formula II1, or a stereoisomer or pharmaceutically acceptable salt thereof:
wherein the abundance of deuterium in Z is selected from: (a) at least 40%, (b) at least 50%,
(c) at least 60%, (d) at least 70%, (e) at least 80%, (f) at least 90%, (g) at least 95%, (h) at least 97%, and (i) about 100%.

### Claim 18 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the compound is of formula IIa1, or pharmaceutically acceptable salt thereof:
wherein the abundance of deuterium in Z is selected from: (a) at least 40%, (b) at least 50%,
(c) at least 60%, (d) at least 70%, (e) at least 80%, (f) at least 90%, (g) at least 95%, (h) at least 97%, and (i) about 100%.

### Claim 19 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the compound is of formula IIb1, or pharmaceutically acceptable salt thereof:
wherein the abundance of deuterium in Z is selected from: (a) at least 40%, (b) at least 50%,
(c) at least 60%, (d) at least 70%, (e) at least 80%, (f) at least 90%, (g) at least 95%, (h) at least 97%, and (i) about 100%.

### Claim 20 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the compound is of formula Ic, or pharmaceutically acceptable salt thereof:
wherein:
n=1; and,
A is selected from H and D.

### Claim 21 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the compound is of formula Id or pharmaceutically acceptable salt thereof:
wherein:
n=1; and,
A is selected from H and D.

### Claim 22 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the compound is of formula I1 or a stereoisomer or pharmaceutically acceptable salt thereof:
wherein the abundance of deuterium in Z is selected from: (a) at least 40%, (b) at least 50%,
(c) at least 60%, (d) at least 70%, (e) at least 80%, (f) at least 90%, (g) at least 95%, (h) at least 97%, and (i) about 100%.

### Claim 23 (depends on 1)

A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.

### Claim 24 (depends on 1)

A method for treating myelodysplastic syndrome comprising:
administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1.
